Ceribell Clears Bedside qEEG + VertigoDx's Mobile Headset

Good morning, HealthTech insiders. Ceribell has a new way to make hours of EEG recordings easier to follow at the bedside. The company announced FDA clearance for software that turns brain activity into continuous trends, including measures clinicians can use when monitoring reduced blood flow or adjusting sedation. The features are expected to reach its platform through a software update in the first half of 2027.

Today’s other two stories examine what point-of-care technology can actually do after clearance. SmartVertigo gives clinicians a portable way to record eye movements during vestibular exams; it does not diagnose stroke. Insera’s CLEAR system offers different aspiration modes for removing certain peripheral blood clots, but its clearance does not establish better patient outcomes than existing devices. The question running through this issue is where faster access to a signal changes care, and where clinicians still need stronger evidence before changing the pathway.

In today's Signal:

• Ceribell adds quantitative EEG trends: Its newly cleared software presents alpha-delta ratio, relative alpha, burst suppression, and amplitude-integrated EEG trends for clinicians monitoring patients across age groups.

• A closer look at SmartVertigo: The portable, prescription-use system records eye movements during vestibular assessment. Its July clearance leaves diagnosis and treatment decisions with the clinician.

• CLEAR moves toward U.S. use: Insera’s previously announced, FDA-cleared system offers cyclical, uniform, and blood saver aspiration modes for fresh, soft clots in peripheral vessels.

• What we’re watching next: Deployment dates, clinical workflow studies, and evidence that these tools improve decisions rather than simply make more data available.

Sponsored by

Stop googling AI tools at midnight.

There are over 3,000 of them in The Shift’s vault, already vetted, ready to explore.

Subscribe and get instant access to the tool vault, a 1000+ prompt library, and free AI courses built for people with actual work to do. 

Plus, the daily newsletter that keeps you sharp on everything moving in AI in under 5 minutes a day.

They’re also giving away a free 1-year Claude Pro subscription to 3 subscribers. 

Subscribe for free to enter. All free. All in one place.

Subscribe to The Shift

CLINICAL & NEUROLOGY
1. Ceribell Announces FDA Clearance for Quantitative EEG Trending

Ceribell announced on September 30 that the FDA had cleared new analysis software for its EEG system. The FDA recorded its clearance decision on September 16. The software presents longitudinal brain activity as trends intended to help clinicians review changes during ongoing monitoring.

The details:

• Brain activity trends: Alpha-delta ratio and relative alpha trending may help clinicians identify changes associated with brain distress or reduced blood flow in high-risk patients, including those with subarachnoid hemorrhage. A trend is a prompt for clinical assessment, not a stand-alone diagnosis of ischemia.

• Sedation monitoring: Burst suppression monitoring gives care teams another view of brain activity when managing severe ongoing seizures or brain swelling and adjusting treatment.

• Across age groups: Amplitude-integrated EEG supports simplified, longer-term monitoring, including neonatal assessment. The clearance has no age restriction, and Ceribell expects to deliver the features through an automatic update in the first half of 2027.

The Signal: Ceribell is making lengthy EEG recordings easier to review where patients are treated. The test now is whether teams can act on those trends reliably within their existing specialist-review and treatment protocols.

DIAGNOSTICS & POINT-OF-CARE
2. What SmartVertigo’s FDA Clearance Means for Bedside Vestibular Exams

SmartVertigo received FDA 510(k) clearance on July 30, 2026. The prescription-use system combines a smartphone app and light-occluding headset to record eye movements in patients aged 12 and older who have symptoms associated with peripheral vestibular disorders. This is a closer look at an earlier clearance, rather than a new September decision.

The details:

• Portable eye-movement recording: Clinicians can use the headset during familiar positional maneuvers and review recorded horizontal, vertical, and torsional eye movements.

• Defined clinical role: The cleared device records, tracks, stores, and displays eye movements. Its stated indication says it does not provide a diagnosis or diagnostic recommendation; a licensed clinician interprets the findings.

• Evidence still developing: VertigoDx says SmartVertigo is being evaluated in an IRB clinical study. Claims that it can rule out cerebellar stroke or safely replace emergency neuroimaging require evidence beyond this clearance.

The Signal: A portable recording may make vestibular findings easier to capture and review outside a dedicated lab. Its value in emergency triage will depend on clinical validation and careful use alongside the rest of the neurological examination.

INTERVENTIONAL MEDTECH & VASCULAR SURGERY
3. A Closer Look at Insera’s CLEAR Cyclical Aspiration System

Insera announced its CLEAR Aspiration System clearance on September 28; the FDA’s clearance decision was June 24. We also mentioned the announcement in the September 29 Signal. Here, the focus is the device’s operating modes and the clinical evidence still needed after clearance.

The details:

• Intended use: CLEAR is designed to remove fresh, soft emboli and thrombi from vessels of the peripheral arterial and venous systems. The system includes a pump and compatible single-use catheters and other disposables.

• Selectable aspiration: Operators can choose cyclical, uniform, or blood saver modes. Insera also reports that the platform holds a CE mark in the European Union.

• Performance question: The clearance was supported by safety and performance testing. It does not establish that CLEAR improves first-pass success, reduces blood loss in patients, or outperforms continuous aspiration in comparative clinical care.

The Signal: Choice of aspiration mode gives interventionists another procedural option. Registries and comparative studies will show whether that flexibility produces a measurable advantage in clot removal, blood use, or procedure time.

👀 WHAT WE'RE WATCHING NEXT

• Ceribell’s rollout: Whether the planned first-half 2027 software update is delivered on schedule and how neuro-ICUs incorporate the new trends into review and escalation protocols.

• SmartVertigo validation: Whether prospective studies establish where portable eye-movement recording improves assessment, without treating the device as a stroke rule-out test.

• CLEAR’s clinical performance: Comparative data on clot removal, procedural time, and blood loss across aspiration modes and existing devices.

💰 FOLLOW THE MONEY

The deals:

• Basecamp Research: A $140 million Series C, led by S32, to develop its EDEN biological models and advance AI-designed therapeutics toward clinical development. The round was announced September 23 and also appeared in our recent coverage.

• Tiny Health: A $33 million Series B, led by B Capital. The company says it has served nearly 200,000 customers and is introducing TinyAI, built on a dataset of nearly 200,000 microbiome profiles. Its intended personalized guidance should not be presented as a validated pediatric treatment decision engine.

• Basalt Health: A $20 million Series A, led by NEA, to expand its post-acute admissions platform. Basalt says it is live at Lifepoint Health and plans to scale across 62 ScionHealth hospitals by the end of 2026; that rollout is a target, not a completed deployment.

The pattern: These investments address different stages of healthcare work: designing therapies, interpreting biological data, and coordinating patient placement. Each company still has to show that its data or automation leads to useful, repeatable outcomes in practice.

📆 UPCOMING HEALTHTECH EVENTS

• Frontiers Health 2026: October 20-21 | Berlin, Germany. A digital health gathering for founders, clinicians, investors, and health industry leaders.

• HLTH USA 2026: November 15-18 | Las Vegas, NV. Healthcare leaders, payers, providers, and technology companies meet across the four-day program.

• RSNA 2026: November 29-December 3 | Chicago, IL. The radiology scientific assembly and annual meeting at McCormick Place.

🛠️ Trending HealthTech AI Tools

• Ceribell EEG Analysis Software: Newly cleared quantitative EEG trends for longitudinal brain monitoring; Ceribell expects the update in the first half of 2027.

• SmartVertigo Vestibular Assessment System: A portable way for clinicians to record and review eye movements during vestibular assessment; it does not issue diagnoses.

• TinyAI: Tiny Health’s newly introduced system for generating personalized guidance from microbiome results. Clinical benefit remains to be established.

🛠️ Trending HealthTech AI Startups

• VertigoDx: Developing portable vestibular assessment tools for clinician-supervised use.

• Insera Therapeutics: Bringing selectable aspiration modes to peripheral mechanical thrombectomy.

• Tiny Health: Expanding microbiome testing, research access, and personalized interpretation following its Series B.

DECISION INTELLIGENCE

Highlights: Deep Dives & Industry Reports

• Decentralizing the Neuro-ICU: How Quantitative EEG Could Change Bedside Triage Economics
  What easier access to EEG trends may mean for review time, specialist workflows, and treatment decisions, and what must be measured after Ceribell’s update reaches hospitals.

• Mobile Optical Diagnostics: Where SmartVertigo Fits in the Emergency Vertigo Workup
  The potential value of portable eye-movement recording, the limits of its cleared indication, and the evidence needed before changing imaging or referral pathways.

• Cyclical Mechanics vs. Static Vacuum: The Next Question in Endovascular Thrombectomy
  How CLEAR’s aspiration modes differ and which comparative clinical results would matter to interventionists and hospital buyers.

That's it for today!

Ceribell’s new clearance puts a clearer view of ongoing EEG activity within reach of bedside teams, though the software update is still ahead. SmartVertigo offers a portable record of eye movements that a clinician must interpret. CLEAR gives interventionists more control over aspiration settings, with comparative clinical performance still to be shown.

All three may change a step in care. The question now is which step actually becomes faster, safer, or more reliable when these systems enter routine workflows, and what evidence will tell us.

See you tomorrow,

Dr. Dereck Mush, MD, MBA

The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.

Was this email forwarded to you? Sign up here.